Cargando…

Switching positions: Assessing the dynamics of conjugational heterogeneity in antibody–drug conjugates using CE‐SDS

Antibody–drug conjugates (ADCs) are a prospective class of new oncology therapeutics with the ability to deliver a cytotoxic drug to a targeted location. The concept appears simple, but ADCs are highly complex due to their intrinsic heterogeneity. Randomly conjugated ADCs, for instance, are composed...

Descripción completa

Detalles Bibliográficos
Autores principales: van den Berg, Eline B. A., Hendriks, Jaap C. W., Elsinga, Everdine W., Eggink, Mark, Dirksen, Eef H. C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10086850/
https://www.ncbi.nlm.nih.gov/pubmed/35907250
http://dx.doi.org/10.1002/elps.202200140
_version_ 1785022232454496256
author van den Berg, Eline B. A.
Hendriks, Jaap C. W.
Elsinga, Everdine W.
Eggink, Mark
Dirksen, Eef H. C.
author_facet van den Berg, Eline B. A.
Hendriks, Jaap C. W.
Elsinga, Everdine W.
Eggink, Mark
Dirksen, Eef H. C.
author_sort van den Berg, Eline B. A.
collection PubMed
description Antibody–drug conjugates (ADCs) are a prospective class of new oncology therapeutics with the ability to deliver a cytotoxic drug to a targeted location. The concept appears simple, but ADCs are highly complex due to their intrinsic heterogeneity. Randomly conjugated ADCs, for instance, are composed of conjugated species carrying between 0 and 8 linker‐drug molecules, with several positional isomers that vary in drug distribution across the antibody. The drug load, expressed as drug‐to‐antibody ratio (DAR), is a critical quality attribute and should be well controlled, together with the distribution of drug molecules. Here, the impact of the duration of disulfide bond reduction on the DAR was investigated by quantitating the (isomeric) DAR species in ADCs produced with varying reduction times. Although hydrophobic interaction chromatography showed a constant DAR value as a function of reduction time, data obtained by non‐reducing CE‐SDS revealed an unexpected dynamic in the positional conjugated isomers. The insights obtained have improved our understanding of the correlation between the disulfide bond reduction, an important step in the manufacturing of a cysteine‐conjugated ADC, and the conjugational heterogeneity.
format Online
Article
Text
id pubmed-10086850
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-100868502023-04-12 Switching positions: Assessing the dynamics of conjugational heterogeneity in antibody–drug conjugates using CE‐SDS van den Berg, Eline B. A. Hendriks, Jaap C. W. Elsinga, Everdine W. Eggink, Mark Dirksen, Eef H. C. Electrophoresis General, Ce & Cec Antibody–drug conjugates (ADCs) are a prospective class of new oncology therapeutics with the ability to deliver a cytotoxic drug to a targeted location. The concept appears simple, but ADCs are highly complex due to their intrinsic heterogeneity. Randomly conjugated ADCs, for instance, are composed of conjugated species carrying between 0 and 8 linker‐drug molecules, with several positional isomers that vary in drug distribution across the antibody. The drug load, expressed as drug‐to‐antibody ratio (DAR), is a critical quality attribute and should be well controlled, together with the distribution of drug molecules. Here, the impact of the duration of disulfide bond reduction on the DAR was investigated by quantitating the (isomeric) DAR species in ADCs produced with varying reduction times. Although hydrophobic interaction chromatography showed a constant DAR value as a function of reduction time, data obtained by non‐reducing CE‐SDS revealed an unexpected dynamic in the positional conjugated isomers. The insights obtained have improved our understanding of the correlation between the disulfide bond reduction, an important step in the manufacturing of a cysteine‐conjugated ADC, and the conjugational heterogeneity. John Wiley and Sons Inc. 2022-08-16 2023-01 /pmc/articles/PMC10086850/ /pubmed/35907250 http://dx.doi.org/10.1002/elps.202200140 Text en © 2022 Byondis BV. Electrophoresis published by Wiley‐VCH GmbH. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle General, Ce & Cec
van den Berg, Eline B. A.
Hendriks, Jaap C. W.
Elsinga, Everdine W.
Eggink, Mark
Dirksen, Eef H. C.
Switching positions: Assessing the dynamics of conjugational heterogeneity in antibody–drug conjugates using CE‐SDS
title Switching positions: Assessing the dynamics of conjugational heterogeneity in antibody–drug conjugates using CE‐SDS
title_full Switching positions: Assessing the dynamics of conjugational heterogeneity in antibody–drug conjugates using CE‐SDS
title_fullStr Switching positions: Assessing the dynamics of conjugational heterogeneity in antibody–drug conjugates using CE‐SDS
title_full_unstemmed Switching positions: Assessing the dynamics of conjugational heterogeneity in antibody–drug conjugates using CE‐SDS
title_short Switching positions: Assessing the dynamics of conjugational heterogeneity in antibody–drug conjugates using CE‐SDS
title_sort switching positions: assessing the dynamics of conjugational heterogeneity in antibody–drug conjugates using ce‐sds
topic General, Ce & Cec
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10086850/
https://www.ncbi.nlm.nih.gov/pubmed/35907250
http://dx.doi.org/10.1002/elps.202200140
work_keys_str_mv AT vandenbergelineba switchingpositionsassessingthedynamicsofconjugationalheterogeneityinantibodydrugconjugatesusingcesds
AT hendriksjaapcw switchingpositionsassessingthedynamicsofconjugationalheterogeneityinantibodydrugconjugatesusingcesds
AT elsingaeverdinew switchingpositionsassessingthedynamicsofconjugationalheterogeneityinantibodydrugconjugatesusingcesds
AT egginkmark switchingpositionsassessingthedynamicsofconjugationalheterogeneityinantibodydrugconjugatesusingcesds
AT dirkseneefhc switchingpositionsassessingthedynamicsofconjugationalheterogeneityinantibodydrugconjugatesusingcesds